Cardiac Repolarization Assays: Identify QT Risk Using a Variety of Repolarization Assays
The ICH S7B guideline (Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals) recognizes that follow-up studies to the hERG (in vitro) and the in vivo models can “provide greater depth of understanding or additional knowledge regarding the potential of test substance for delayed ventricular repolarization and QT interval prolongation in humans.” ChanTest Corp. offers a variety of in vitro and ex vivo models that characterize a drug’s potential to affect ventricular repolarization, excitation, conduction and contractility. Early testing for multiple effects on key cardiac ion channels, along with ex vivo and in vivo APD/QT measurements, fully resolves discordances and prevents advancement of cardiotoxic drug candidates.
- Detect effects on action potential prolongation (QT risk) and EADs (Torsade trigger)
- Stable recordings at physiological temperature.
- Minimal diffusion delays.
- Detect effects on Action Potential Duration, Upstroke, Amplitude and Resting Membrane Potential